Amarin Corp. (AMRN) Tops Q3 EPS by 2c, Revenues Miss

Amarin Corp. (NASDAQ: AMRN) reported Q3 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.73 million versus the consensus estimate of $60.73 million.

“The landmark results of the REDUCE-IT study present an important opportunity to improve the practice of medicine with respect to preventative cardiovascular care. We believe that these outcomes study results position Vascepa to address a significant unmet medical need and could be considered the most significant breakthrough in preventative cardiovascular care since the advent of statin therapy decades ago. We are very excited about the potential for Vascepa to help millions of patients and we are acting accordingly to expand on our established commercial foundation, including existing broad managed care coverage and extensive key opinion leader support,” stated John F. Thero, president and chief executive officer. “Amarin looks forward to the primary REDUCE-IT outcomes study results being presented at AHA and to working towards the future publication of these results in a major medical journal within 2018.”

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition